Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DTIL
Precision BioSciences, Inc. (DTIL) Altman Z-score
Precision BioSciences, Inc.'s Altman Z-score for fiscal 2025 is −4.31, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −4.31 | (0.13) |
| FY2024 | −4.18 | (0.12) |
| FY2023 | −4.06 | (1.84) |
| FY2022 | −2.22 | (2.93) |
| FY2021 | 0.71 | 2.67 |
| FY2020 | −1.96 | (4.23) |
| FY2019 | 2.28 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.71 | — | 0.85 | |
| Retained earnings / total assets | (3.42) | — | −4.79 | |
| EBIT / total assets | (0.34) | — | −1.11 | |
| Market value of equity / total liabilities | 0.86 | — | 0.51 | |
| Sales / total assets | 0.22 | — | 0.22 | |
| Altman Z-score | Distress zone | −4.31 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −7.20 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | 4.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.9× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.5× |
| DTIL Precision BioSciences, Inc. | −4.3× |
| ADAG Adagene Inc. Sponsored ADR compare | −4.6× |
| CHRS Coherus Oncology, Inc. compare | −8.8× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | −11.2× |
| VRXA Veraxa Biotech AG compare | — |
| PEPG PepGen, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets